Ownership and insider activity for BridgeBio Pharma, Inc. (BBIO): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
BridgeBio Pharma, Inc. is a pharmaceutical company dedicated to identifying, advancing, and providing medical solutions for various genetic conditions. The firm boasts an extensive portfolio comprising 30 distinct development initiatives, spanning the entire spectrum from initial discovery research to advanced clinical trial phases.
Price
| Price | $66.14 |
| Market Cap | $13.0B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-17 | Kumar Neil | S-Sale | 8,721 | $602K |
| 2026-09-17 | Kumar Neil | S-Sale | 1,279 | $89K |
| 2026-08-19 | Kumar Neil | S-Sale | 8,100 | $679K |
| 2026-08-19 | Kumar Neil | S-Sale | 1,800 | $152K |
| 2026-08-19 | Kumar Neil | S-Sale | 100 | $9K |
| 2026-08-18 | Kumar Neil | S-Sale | 1,900 | $154K |
| 2026-08-18 | Kumar Neil | S-Sale | 17,279 | $1.4M |
| 2026-08-18 | Kumar Neil | S-Sale | 14,602 | $1.2M |
| 2026-08-18 | Kumar Neil | S-Sale | 1,199 | $100K |
| 2026-08-16 | Trimarchi Thomas | F-InKind | 22,781 | $1.8M |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $92.0M | $436.1M | $363.8M | $356.1M | $393.8M | $376.7M | $375.9M | $681.1M | $570.1M |
| Short-term Investments | 0 | 0 | $182.2M | $251.0M | $442.9M | $95.2M | $58.9M | 0 | $17.4M |
| Receivables | 0 | 0 | $2.8M | 0 | $19.7M | $17.1M | $1.8M | $4.7M | $139.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $26.8M |
| Total Current Assets | $97.1M | $445.2M | $568.6M | $642.8M | $888.9M | $548.9M | $477.6M | $720.7M | $753.7M |
| Property, Plant & Equipment | $440,000 | $1.6M | $5.6M | $36.8M | $46.0M | $25.2M | $19.8M | $12.8M | $13.5M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $44.9M | $28.7M | $26.3M | $23.9M | $28.1M |
| Total Assets | $98.0M | $464.9M | $631.7M | $703.6M | $1.01B | $623.0M | $546.4M | $919.3M | $936.0M |
| Accounts Payable | $1.9M | $13.5M | $8.9M | $8.9M | $11.9M | $11.6M | $10.7M | $9.6M | $36.2M |
| Short-term Debt | 0 | 0 | 0 | $1.5M | 0 | 0 | 0 | 0 | $17.4M |
| Total Current Liabilities | $8.6M | $32.6M | $60.4M | $95.6M | $135.1M | $121.4M | $143.8M | $154.4M | $288.0M |
| Long-term Debt | $143.9M | $54.5M | $91.8M | $475.9M | $1.70B | $1.71B | $1.73B | $1.72B | $2.71B |
| Total Liabilities | $152.7M | $566.4M | $155.7M | $595.7M | $1.88B | $1.87B | $1.89B | $2.38B | $3.01B |
| Retained Earnings | -$61.4M | -$170.6M | -$440.0M | -$888.8M | -$1.44B | -$1.92B | -$2.56B | -$3.10B | -$3.82B |
| Total Equity | -$58.0M | -$164.0M | $408.5M | $57.9M | -$870.4M | -$1.25B | -$1.35B | -$1.47B | -$2.08B |
| Total Debt | $143.9M | $54.5M | $91.8M | $495.8M | $1.73B | $1.72B | $1.74B | $1.73B | $2.73B |
| Net Debt | $51.9M | -$381.6M | -$454.2M | -$111.3M | $889.5M | $1.25B | $1.30B | $1.05B | $2.14B |
| Working Capital | $88.6M | $412.6M | $508.2M | $547.2M | $753.8M | $427.4M | $333.7M | $566.3M | $465.7M |
Financial Health
| Debt / Equity | -0.99 |
| Current Ratio | 1.23 |
| Piotroski F-Score | 2 |
| Altman Z-Score | -3.58 |
Profitability
| Return on Equity | 31.67% |
| Return on Invested Capital | -61.77% |
| Return on Assets | -57.20% |
| Gross Margin | 93.14% |
| Operating Margin | -78.56% |
| Net Margin | -100.64% |
Related companies: ASND · BMRN · EXEL · IONS · JAZZ · MRNA · RNA
Explore sector: Healthcare · Biotechnology
More sections of BBIO: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Investment Academy — learn to analyze stocks